Every pharma commercial leader knows the feeling. You’ve spent years building a blockbuster brand, navigating market access hurdles, defending your formulary position… and then the patent cliff looms. One moment you’re forecasting steady growth, the next you’re watching 70-90% of your revenue evaporate in twelve months.
The brutal reality? Loss of Exclusivity (LOE) events represent $300-400 billion in sales at risk through 2030, and the traditional playbook isn’t working anymore. Generic competition hits faster. Payers shift formularies overnight. And those analog-based erosion curves you’ve relied on? They’re increasingly unreliable in today’s market.
Here’s what I’ve noticed after supporting dozens of LOE transitions: the companies that navigate patent expiry successfully aren’t the ones with the biggest brands—they’re the ones with the most sophisticated data-driven forecasting, the clearest market impact models, and the earliest preparation timelines.
Why LOE Forecasting Has Become Exponentially More Complex
Patent expiry used to follow predictable patterns. Small molecules faced rapid generic erosion, biologics maintained premium positioning longer, and your financial models could benchmark against historical analogs with reasonable confidence.
Not anymore.
The modern LOE landscape involves multiple moving parts that traditional forecasting struggles to capture. You’re dealing with Paragraph IV patent challenges that can shift entry timing by years. Regulatory exclusivities like New Chemical Entity designations or pediatric extensions complicate patent expiry calculations. Litigation settlements introduce authorized generic agreements. And payer behavior has shifted dramatically—formulary exclusions happen faster, rebates become more aggressive, and brand loyalty evaporates.
Meanwhile, the difference between small-molecule and biologic LOE events has widened significantly. Small molecules still face that devastating first-year cliff, but biologics are experiencing their own transformation, particularly in therapeutic areas like oncology and immunology where biosimilar competition is finally gaining traction.
What makes this especially challenging for forecasting teams is the data fragmentation. You need accurate patent databases, real-world claims data showing treatment switching patterns, payer contracting intelligence, competitive entry predictions, and pricing dynamics—all integrated into models that can simulate multiple scenarios. Most companies don’t have this infrastructure.
The Three Pillars of Accurate LOE Market Impact Analysis
After analyzing hundreds of patent expiry events, the companies with the most reliable forecasts consistently focus on three interconnected elements: timing precision, analog selection quality, and real-world data integration.
Timing Precision: Beyond Simple Patent Expiry Dates
The first mistake most teams make? Treating patent expiry as a single date rather than a probability distribution across multiple scenarios.
Accurate LOE timing requires monitoring several layers simultaneously. The FDA Orange Book provides your baseline—patent listings and exclusivity data for approved drugs. But that’s just the starting point. You need to track Patent Term Adjustments (PTAs) and Patent Term Extensions (PTEs) that can add months or years. You need litigation intelligence showing which patents face Paragraph IV challenges and the historical success rates of those challenges. You need regulatory exclusivity overlays—orphan drug designations, pediatric extensions, data exclusivity periods.
Sophisticated patent intelligence platforms aggregate these data sources, but the real value comes from probabilistic modeling. Instead of saying “generic entry in Q3 2026,” your forecasts should reflect scenarios: 40% probability Q2 2026 if litigation settles early, 35% probability Q4 2026 if appeals extend, 25% probability Q2 2027 if additional patents hold.
This matters enormously for commercial planning. A six-month shift in generic entry timing can mean the difference between hitting annual targets and missing by $200+ million.
Analog Selection: Moving Beyond Simplistic Benchmarking
Now here’s where traditional LOE modeling frequently fails: analog selection.
The standard approach involves finding “similar” past LOE events—same therapeutic area, similar competitive dynamics, comparable pricing—and applying their erosion curves to your forecasts. Historical analog benchmarking remains the foundation for most industry forecasting, but it’s evolved significantly.
The problem is that market conditions in 2020 differ dramatically from 2015, which differ dramatically from 2010. Payer consolidation has accelerated. Formulary exclusions happen faster. Rebate levels have intensified. Patient cost-sharing structures have changed. Using a 2015 analog for a 2026 LOE event might give you directionally correct insights but operationally misleading forecasts.
Better analog selection requires multiple dimensions of matching. You need therapeutic area alignment, obviously. But you also need payer landscape similarity—did the analog face similar formulary pressure? Number of generic entrants—one competitor versus ten produces radically different erosion. First-generic timing—early entry versus staggered launches. Authorized generic presence—this dramatically impacts both generic and brand pricing. Biosimilar versus small-molecule classification—completely different archetypes.
And then you layer in the macro environment. What were rebate levels at the time? How aggressive were payer tactics? What was the broader pricing environment?
The most sophisticated forecasting teams don’t rely on a single analog. They create weighted composite curves from multiple comparable events, adjusting for market evolution and therapeutic area specifics.
Real-World Data Integration: Claims Data as Your LOE Crystal Ball
This is where most LOE forecasting models fall short—they rely too heavily on historical abstractions and not enough on actual patient behavior data.
Real-world evidence, particularly longitudinal insurance claims data, provides direct visibility into what actually happens when brands lose exclusivity. You can track brand-to-generic switching rates by patient cohort. You can see how quickly physicians change prescribing patterns. You can measure payer formulary impacts on utilization. You can identify which patient segments remain on branded products longest—and why.
The value here isn’t just descriptive—it’s predictive. If you’re preparing for LOE in oncology, analyzing claims data from previous oncology LOE events shows you that switching patterns differ dramatically by line of therapy. First-line patients switch faster than later-line patients. Certain oncologist practice types maintain brand loyalty longer. Specific payer types drive substitution more aggressively.
These insights transform your erosion models from generic curves to segmented forecasts with defensible assumptions. Instead of “70% erosion in year one,” you’re modeling “75% erosion in commercially-insured first-line patients, 60% erosion in government-subsidized second-line patients, 45% erosion in third-line specialty pharmacy patients.”
The companies winning at LOE forecasting integrate claims-based utilization datasets into every stage of their analysis.
Advanced LOE Modeling Techniques That Actually Work
Beyond the foundational pillars, certain modeling approaches consistently produce more accurate forecasts—particularly when dealing with the increased complexity of modern patent cliffs.
Archetype-Based Modeling: Small Molecule vs. Biologic LOE
If you’re applying the same forecasting methodology to small molecules and biologics, you’re doing it wrong.
Small-molecule LOE events follow that classic devastating pattern: 70-90% revenue erosion in the first year, driven by rapid generic entry (often 5-10+ competitors within months), automatic substitution laws, aggressive payer formulary shifts, and dramatic price erosion. The generic price typically drops 80-90% from brand pricing almost immediately.
Biologics? Completely different story. Biosimilar erosion happens more gradually—20-40% in year one is more typical. Why? Manufacturing complexity limits the number of entrants. No automatic substitution exists in most markets. Physicians require more education and comfort with interchangeability. Patients and providers maintain brand loyalty longer, especially in oncology and immunology. And pricing erosion is less severe—biosimilars typically launch at 15-30% discounts, not 80-90%.
The oncology patent cliff illustrates this perfectly. Blockbuster biologics like Keytruda and Opdivo will face LOE in the coming years, but the market impact will unfold over 5-7 years rather than 12 months.
Your forecasting models need distinct archetypes for each scenario, with different assumptions about entrant numbers, pricing dynamics, switching timelines, and market access impacts.
Scenario Planning and Risk Assessment
Single-point forecasts are essentially fiction. The future is a probability distribution, and your LOE models should reflect that reality.
Effective scenario planning involves modeling three to five distinct futures, each with assigned probabilities. Your base case might assume standard generic entry with 4-6 competitors, moderate payer pressure, and typical erosion curves. Your pessimistic scenario models early generic entry, aggressive payer exclusions, 10+ competitors, and accelerated erosion. Your optimistic scenario assumes litigation delays, limited generic competition, or successful authorized generic positioning that captures generic margin.
But the real sophistication comes from dynamic scenario modeling—not static snapshots but evolving probabilities that update as new intelligence emerges. Litigation outcomes shift entry timing. Competitor financial difficulties reduce expected entrants. Payer consolidation changes contracting dynamics. Your models should reflect these probability shifts in real-time.
This allows your commercial and finance teams to make risk-adjusted decisions with confidence intervals rather than false precision.
Predictive Analytics and Machine Learning Integration
Traditional statistical methods—time series forecasting, regression analysis, analog benchmarking—provide your foundation. But advanced analytics significantly improves forecast accuracy, especially for complex LOE scenarios.
Machine learning models excel at identifying non-obvious patterns across hundreds of variables simultaneously. Which combination of factors best predicts first-generic entry timing? How do physician specialty distributions impact switching rates? What payer characteristics correlate with aggressive formulary exclusions? Neural networks and ensemble methods can surface insights that traditional analysis misses.
The key is hybrid modeling—combining the interpretability and industry logic of traditional approaches with the pattern recognition capabilities of machine learning. You’re not replacing analog curves with black-box algorithms; you’re enhancing human expertise with computational power.
Several specialized platforms now offer AI-enhanced LOE forecasting, integrating patent data, claims analytics, and predictive modeling into unified workflows.
Understanding Your Data Partnership Options for LOE Analysis
Accurate LOE forecasting depends entirely on data quality and integration across multiple domains. You can’t build reliable models on incomplete or fragmented information. The challenge many pharmaceutical companies face isn’t finding data providers—it’s determining which combination of capabilities aligns with their strategic priorities.
Patent and Exclusivity Intelligence
Your first requirement is comprehensive patent and regulatory exclusivity data. This goes beyond simple Orange Book lookups to include patent family analysis, litigation tracking, extension calculations, and global patent landscapes if you’re modeling international markets.
Patent intelligence platforms consolidate this information, but you need regular updates—patent challenge filings, court decisions, and settlement agreements can change your timeline overnight.
The market includes providers ranging from comprehensive databases covering global patent families to specialized services focused on specific therapeutic areas or regions. Key evaluation criteria include update frequency (daily vs. weekly), litigation intelligence depth, analyst support quality, and API integration capabilities.
Claims-Based Utilization and Switching Data
This is where real-world evidence becomes indispensable. Longitudinal insurance claims data provides direct visibility into treatment patterns, switching behaviors, and market dynamics during LOE events.
You need datasets covering pre-LOE utilization (baseline brand volume), immediate post-LOE switching rates (brand-to-generic conversion timing), patient persistence patterns (who stays on brand and why), and long-term market share evolution (stabilization points and niche brand positioning).
The granularity matters enormously. Aggregate national data tells you one story; segmented data by payer type, patient demographics, physician specialty, and geographic region tells you actionable stories you can actually operationalize in commercial planning.
Coverage breadth varies dramatically across the data landscape. Some providers maintain longitudinal records covering hundreds of millions of patient lives across multiple regions and payer types. Others focus on specific populations or geographies with greater depth. Understanding which coverage model matches your therapeutic areas and target markets requires careful evaluation.
Payer Behavior and Market Access Intelligence
Understanding how payers respond to LOE events—formulary positioning changes, rebate escalations, prior authorization requirements, step therapy implementations—directly impacts your erosion forecasts.
The challenge is that payer strategies vary significantly by plan type (commercial vs. government-subsidized vs. regional programs), by therapeutic area (payers treat oncology LOE differently than diabetes LOE), and by competitive intensity (one generic versus ten generics triggers different payer responses).
Market access datasets tracking formulary changes, rebate benchmarks, and utilization management policies help you build realistic payer response assumptions into your models. The landscape includes options ranging from comprehensive formulary tracking services to specialized rebate intelligence platforms to integrated analytics combining multiple payer intelligence sources.
Competitive Intelligence and Generic Entry Tracking
You need visibility into which generic manufacturers have filed ANDAs (Abbreviated New Drug Applications), their approval status, manufacturing readiness, and likely launch timing. Tracking LOE to anticipate generic launches requires monitoring FDA approval queues, manufacturing inspection outcomes, and competitive strategies.
The number of generic entrants dramatically impacts pricing and erosion dynamics—one competitor versus six competitors produces completely different market structures.
Navigating this landscape requires expertise in both pharmaceutical commercialization and the evolving real-world evidence ecosystem. The gap between understanding what claims data can do and identifying which specific capabilities match your needs is substantial—this is where expert guidance becomes critical.
Strategic Preparation: Turning LOE Risk Into Managed Transition
Accurate forecasting is necessary but insufficient. The companies that successfully navigate patent cliffs don’t just predict erosion—they actively shape the post-LOE landscape.
The 18-36 Month Pre-LOE Planning Window
Effective LOE strategy begins 18 to 36 months before patent expiry, not six months before. This planning window allows for meaningful intervention strategies that actually work.
Navigating pharma LOE requires cross-functional coordination across commercial, medical affairs, market access, legal, supply chain, and finance teams. Each function brings critical capabilities: commercial develops brand equity preservation tactics, market access negotiates payer positioning, legal manages patent strategy and authorized generic planning, supply chain prepares for volume shifts.
The earlier you align these functions around shared LOE forecasts and scenarios, the more strategic options you preserve.
Lifecycle Management and Market Defense Strategies
Companies with successful LOE outcomes typically pursue multiple defense strategies simultaneously rather than relying on single tactics.
New formulations or delivery mechanisms—extended-release versions, combination products, new routes of administration—can extend patent protection and create differentiated branded alternatives. New indication development provides additional exclusivity periods and expands addressable markets. Authorized generic partnerships allow capturing generic margin while controlling market dynamics. Patient support programs and loyalty initiatives maintain brand relationships beyond LOE.
The key is realistic assessment of each strategy’s probability of success and revenue impact, integrated into your scenario planning.
Portfolio Diversification and Pipeline Investment
Here’s the uncomfortable truth: no amount of forecasting sophistication or defense strategy compensates for portfolio over-concentration on blockbusters approaching LOE.
The companies experiencing the most severe patent cliff impacts are those that failed to invest adequately in pipeline diversification. When 40-60% of revenue faces LOE within a three-year window and your pipeline can’t offset it, you’re facing existential business challenges no amount of modeling can solve.
LOE forecasting should drive strategic portfolio decisions years in advance—accelerating development programs, prioritizing indications, informing M&A strategy, and allocating R&D investment toward therapeutic areas with long-term growth potential.
Common LOE Forecasting Mistakes That Destroy Forecast Accuracy
After reviewing dozens of LOE forecasting models that dramatically missed their targets, certain patterns emerge repeatedly. These aren’t minor technical errors—they’re fundamental conceptual mistakes that cascade through entire forecasts.
Over-Reliance on Outdated Analog Events
Using a 2012 LOE analog to forecast a 2026 patent expiry ignores a decade of market evolution. Payer behavior has shifted, generic competition has intensified, rebate dynamics have changed, and patient cost-sharing structures have evolved. Your analog selection must account for market condition evolution.
Ignoring Payer Consolidation and Formulary Dynamics
The three largest PBMs now control over 80% of prescription volume in the US. This consolidation dramatically accelerates post-LOE formulary exclusions and rebate pressures. Models built on pre-consolidation dynamics will systematically underestimate brand erosion.
Underestimating Generic Entrant Numbers
Forecasting assumes 2-3 generic competitors, but 8-10 actually enter the market. This dramatically accelerates price erosion and volume shifts. Your competitive intelligence must accurately predict likely entrant numbers based on market attractiveness and manufacturing capacity.
Treating All Patient Segments Identically
Aggregate erosion curves hide critical segmentation. Commercial patients switch faster than government-subsidized patients. First-line therapy patients switch faster than later-line patients. Specialty pharmacy channels maintain brand loyalty longer than retail channels. Segmented forecasting produces operationally useful insights that aggregate models miss.
Optimism Bias in Internal Forecasts
Internal stakeholder pressure pushes forecasts toward optimistic scenarios—better brand retention, slower generic uptake, premium pricing maintenance. This creates planning assumptions that consistently disappoint, eroding forecast credibility across the organization. Independent, data-driven forecasting processes with external benchmarking help counteract this bias.
Key Considerations in Building LOE Forecasting Capabilities
Several dimensions separate adequate from excellent LOE forecasting infrastructure. Understanding these trade-offs helps you evaluate what combination of capabilities your organization truly needs.
Data Recency and Update Frequency
Some data sources provide near-real-time insights updated daily or weekly, while others work with adjudicated claims on quarterly cycles. Real-time data enables faster pattern recognition but may include noise from incomplete claims. Adjudicated data offers greater accuracy but introduces lag that can miss early signals.
The right choice depends on your use case. Tracking rapidly-evolving competitive dynamics benefits from real-time feeds. Building validated erosion curves for strategic planning works better with clean, adjudicated data.
Analytical Sophistication and Self-Service Capabilities
Capabilities range from traditional query-based systems requiring significant internal analytics expertise to AI-powered platforms offering real-time pattern recognition and predictive insights with minimal technical overhead. Some solutions provide raw data requiring extensive internal processing; others deliver analysis-ready insights.
Consider your internal capabilities honestly. Self-service platforms empower teams with strong data science expertise. Full-service analytics partnerships work better when internal resources are constrained.
Integration and Workflow Compatibility
How well do prospective data sources integrate with your existing forecasting infrastructure? API access, data format compatibility, and schema documentation quality vary dramatically. Some providers offer seamless integration with common forecasting platforms; others require substantial data engineering.
The gap between licensing claims data and extracting actionable intelligence is substantial. Integration friction multiplies time-to-insight and can derail projects entirely.
Domain Expertise and Consulting Support
Pure data provision differs fundamentally from data provision combined with pharmaceutical domain expertise. Some providers offer therapeutic area specialists who understand your business context. Others provide excellent data infrastructure but limited interpretation guidance.
For complex LOE scenarios involving novel biosimilar competition or therapeutic areas with limited historical precedent, access to experts who’ve navigated similar situations becomes invaluable.
Cost Models and Contractual Flexibility
Pricing structures range from usage-based models charging per query or patient cohort to enterprise licenses providing unlimited access. Initial pilots may require minimum commitments or offer flexible month-to-month arrangements.
Understanding your likely usage patterns helps match the right commercial model. Underestimating your data needs leads to cost overruns; overcommitting to enterprise licenses wastes resources if you’re still validating use cases.
Expert advisors who understand both your business objectives and the data landscape can accelerate your path to value while avoiding costly mismatches between capabilities and requirements.
Frequently Asked Questions About Loss of Exclusivity Forecasting
How far in advance should LOE forecasting begin?
Strategic LOE planning should begin 18-36 months before expected patent expiry, with initial forecasting starting even earlier for major brands. This allows sufficient time for lifecycle management strategies, authorized generic planning, and commercial preparation.
What’s the typical revenue erosion for small-molecule drugs post-LOE?
Small molecules typically experience 70-90% revenue erosion in the first year after generic entry, driven by rapid generic competition, automatic substitution, and aggressive payer formulary shifts.
How do biologic LOE events differ from small-molecule patent expiry?
Biologics erode more gradually—typically 20-40% in year one—due to manufacturing complexity limiting entrants, no automatic substitution, physician education requirements, and less severe pricing pressure. The erosion curve extends over 5-7 years rather than 12-18 months.
What role does claims data play in LOE forecasting?
Longitudinal claims data provides direct visibility into actual patient switching behaviors, physician prescribing pattern changes, and payer formulary impacts during LOE events. This real-world evidence dramatically improves forecast accuracy by replacing assumptions with observed behaviors.
How do authorized generics impact LOE dynamics?
Authorized generics allow brands to capture generic margin while potentially limiting independent generic competition. They typically launch at LOE or slightly before, influencing both pricing dynamics and market share distribution between brand and independent generics.
What’s the biggest mistake companies make in LOE preparation?
Starting too late. Companies that begin serious LOE planning 6-12 months before patent expiry have limited strategic options remaining. Effective defense strategies—new formulations, indication expansions, lifecycle management—require 2-3+ years of development.
How do I evaluate different data sources for LOE forecasting?
Define your requirements clearly first: coverage needs (geographies, therapeutic areas, patient populations), analytical capabilities required (self-service vs. full-service), integration requirements (API access, data formats), compliance constraints, and budget parameters. Understanding which combination of coverage, analytical tools, and domain expertise matches your specific needs requires deep market knowledge. Expert consultants can help structure this requirements definition process to ensure you’re comparing options on dimensions that actually matter for your use cases.
Building Confidence Through Strategic LOE Preparation
The patent cliff isn’t disappearing—if anything, the stakes keep increasing as more blockbusters approach exclusivity. But the companies navigating LOE successfully aren’t victims of circumstance; they’re leveraging sophisticated data, advanced modeling, and early strategic planning to turn uncertainty into managed transitions.
The challenge isn’t just acquiring data—it’s knowing which data sources align with your strategic priorities, how to integrate them into actionable forecasting models, and when to leverage external expertise versus building internal capabilities.
Most companies overlook critical considerations when evaluating their LOE forecasting infrastructure. They focus on data coverage without considering analytical sophistication. They prioritize cost over integration complexity. They underestimate the value of domain expertise in interpreting results.
Understanding which approaches and capabilities match your organization’s specific needs—across therapeutic areas, use cases, internal resources, and strategic objectives—requires guidance from professionals who understand both the pharmaceutical industry and the evolving real-world evidence ecosystem.
Where Expert Navigation Makes the Difference
Before evaluating specific approaches, define your requirements clearly. What LOE events do you face in the next 36 months? Which therapeutic areas require the deepest analysis? What level of forecast precision do your stakeholders demand? Do you need descriptive intelligence or predictive insights?
The gap between understanding what LOE forecasting requires and assembling the right combination of data sources, analytical capabilities, and domain expertise is substantial. Companies that succeed typically leverage external advisors early in the process—not to outsource the work, but to navigate the complex landscape of options with confidence.
Expert advisors who know both your business objectives and the data landscape can accelerate your path to value while avoiding common pitfalls: data sources that don’t cover your key therapeutic areas, analytical platforms that don’t integrate with your workflows, cost structures that don’t match your usage patterns, or capabilities that solve yesterday’s problems instead of tomorrow’s challenges.
Your Next Steps: Transforming LOE Uncertainty Into Strategic Advantage
If you’re facing significant LOE events in the next 18-36 months—and honestly, most pharma portfolios face meaningful patent cliffs in that window—now is the time to evaluate your analytical infrastructure.
Start by honestly assessing your current capabilities:
- Do you have access to comprehensive patent intelligence that updates in real-time?
- Are your erosion models based on truly comparable analogs adjusted for market evolution?
- Have you integrated longitudinal claims data showing actual patient switching behaviors?
- Can you model multiple scenarios with assigned probabilities?
- Does your team have the bandwidth and expertise to execute sophisticated LOE forecasting internally?
The difference between accurate forecasting and wishful thinking is measured in hundreds of millions of dollars. When patent expiry represents billions in revenue at risk, strategic preparation isn’t optional—it’s the only competitive approach that works.
At MEDDDICAL, we help pharmaceutical companies navigate the complex landscape of real-world evidence for LOE forecasting and commercial analytics. We understand both the strategic questions you’re trying to answer and the evolving ecosystem of data sources, analytical platforms, and methodological approaches available to answer them.
Our expertise lies in helping you define requirements clearly, evaluate options systematically, and identify the right combination of capabilities that align with your specific business objectives—whether that involves claims data integration, predictive analytics platforms, domain expertise, or strategic guidance on LOE preparation.
Explore our approach to commercial analytics strategy to understand how we help companies transform LOE uncertainty into managed transitions.
Ready to discuss your specific LOE forecasting challenges and explore strategic approaches to real-world intelligence?
Contact us for a consultation to discuss your data requirements, analytical objectives, and strategic priorities. We’ll help you understand which approaches and capabilities match your needs—and navigate the complex landscape with confidence.
Because when billions in revenue hang in the balance, expert guidance isn’t a luxury. It’s the foundation of every successful LOE strategy.
Sources & References
- IQVIA. “The Rules of Loss of Exclusivity Are Being Rewritten.” 2025. https://www.iqvia.com/locations/united-states/blogs/2025/07/the-rules-of-loss-of-exclusivity-are-being-rewritten
- Evaluate (J+D Forecasting). “Expert Insights: How to Model for Loss of Exclusivity and Generic Entrants.” https://www.evaluate.com/thought-leadership/expert-insights-from-jd-forecasting-how-to-model-for-loss-of-exclusivity-and-generic-entrants/
- DrugPatentWatch. “Advanced Models for Predicting Pharma Stock Performance in the Face of Patent Expiration.” https://www.drugpatentwatch.com/blog/advanced-models-for-predicting-pharma-stock-performance-in-the-face-of-patent-expiration/
- EY. “Navigating Pharma Loss of Exclusivity.” https://www.ey.com/en_us/insights/life-sciences/navigating-pharma-loss-of-exclusivity
- U.S. Food and Drug Administration. “Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).” https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
- U.S. Food and Drug Administration. “Frequently Asked Questions on Patents and Exclusivity.” https://www.fda.gov/drugs/development-approval-process-drugs/frequently-asked-questions-patents-and-exclusivity
- DrugPatentWatch. “6 Ways to Maximize Product Value as Loss of Exclusivity Approaches.” https://www.drugpatentwatch.com/blog/6-ways-to-maximize-product-value-as-loss-of-exclusivity-approaches/
- IQVIA Institute. “Price Declines After Branded Medicines Lose Exclusivity in the U.S.” https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/price-declines-after-branded-medicines-lose-exclusivity-in-the-us.pdf
- DrugPatentWatch. “The Role of Litigation Data in Predicting Generic Drug Launches.” https://www.drugpatentwatch.com/blog/the-role-of-litigation-data-in-predicting-generic-drug-launches/
- Clarivate. “Tracking Loss of Exclusivity to Anticipate Generic Drug Launches.” https://clarivate.com/life-sciences-healthcare/lp/tracking-loss-of-exclusivity-to-anticipate-generic-drug-launches/
- Intelligencia. “Oncology Patent Cliff Analysis.” https://www.intelligencia.ai/oncology-patent-cliff/
- BioPharma Dive. “Pharma’s Patent Cliff for Biologic Drugs.” https://www.biopharmadive.com/news/pharma-patent-cliff-biologic-drugs-humira-keytruda/642660/
Category: Commercial Analytics for Pharmaceuticals
Related Articles:
Previous: Pharma Market Sizing with Real-World Insurance Claims Data
Next: AI in Pharma: Forecasting, Models & Analytics for New Product Planning
